- Home
- APGE
as 11-21-2025 3:37pm EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.4B | IPO Year: | 2023 |
| Target Price: | $97.33 | AVG Volume (30 days): | 730.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.20 - $67.66 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Nov 13 '25 | Sell | $63.37 | 20,000 | $1,260,236.10 | 1,289,647 | |
| Henderson Jane | APGE | Chief Financial Officer | Nov 11 '25 | Sell | $60.00 | 1,000 | $60,000.00 | 199,871 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Mizuho Initiates Apogee Therapeutics at Outperform With $105 Price Target
Insider Monkey
a month ago
BTIG Maintains a Buy on Apogee Therapeutics (APGE)
Insider Monkey
2 months ago
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating
MT Newswires
2 months ago
Apogee Therapeutics Shares Poised for Upside as Pipeline Targets Multiple Immunology Indications, RBC Says
Simply Wall St.
2 months ago
Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025
GlobeNewswire
2 months ago
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
Zacks
5 months ago
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
GlobeNewswire
6 months ago
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Compare APGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.